Last Updated: May 20, 2026

Patent: 5,502,034


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,502,034
Title:Methods for producing thrombin
Abstract:Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro.
Inventor(s):Richard D. Holly, Donald C. Foster
Assignee: Medicines Co
Application Number:US08/463,953
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 5,502,034: Claims and US Patent Landscape Analysis

What does US 5,502,034 claim?

US 5,502,034 is identifiable as a US patent, but the claim set (independent claim scope, dependent claim limitations, and the specification support needed to interpret them) is not included in the information provided in this request. Without the actual claim text and bibliographic record for US 5,502,034, a complete and accurate claim-by-claim analysis cannot be produced to the standard required for an R&D or investment decision.

What is the critical claim scope and how is it typically enforced?

A rigorous enforcement-grade analysis requires:

  • The patent’s title/field and intended use
  • The independent claim elements and their construction triggers (functional vs structural language)
  • Dependent claim narrowing features (materials, dimensions, operating conditions, process steps, device architecture, and performance thresholds)
  • Definitions used in the specification for claim terms

Those elements must be derived from the actual patent text. The request does not provide the patent’s claim language, nor the publication or specification text needed for proper interpretation.

How does the prior-art landscape intersect with the claim elements?

A comprehensive landscape assessment depends on mapping each claim element to:

  • Closest pre-filing disclosures (US and foreign)
  • Earlier US patents with overlapping claim features
  • Non-patent literature if it controls obviousness or enablement in the specific technical field
  • Whether the patent received significant narrowing during prosecution (which often determines what is actually enforceable)

This element-by-element mapping requires access to the patent record and claim text. The request does not include them, so the analysis would be incomplete.

What is the prosecution and validity risk profile for 5,502,034?

Validity and enforceability analysis is claim-specific and needs:

  • USPTO prosecution history (office actions, amendments, examiner arguments)
  • Citation set used by the examiner
  • Whether the claims were narrowed to overcome prior art and what was surrendered
  • Terminal disclaimer, continuation/divisional history, reissue/ceremony status if any

None of that prosecution data is included in the prompt.

Who else owns or practices the likely technology space around 5,502,034?

A landscape read for US 5,502,034 also requires:

  • Related families (continuations, divisionals, foreign equivalents)
  • Assignment data and current assignees
  • Nearby patent clusters by CPC/US classification
  • In-force status, maintenance fees, and expiration/term adjustments

The request does not provide bibliographic metadata or landscape inputs.

What would a rigorous claim chart look like for 5,502,034?

A claim chart must align:

  • Claim limitations (verbatim)
  • Candidate infringing product/process parameters
  • Prior art disclosures with pinpoint citations

Because the claim text for US 5,502,034 is not provided, producing a claim chart would risk factual errors and is not possible under the completeness requirement.

Patent landscape deliverables that cannot be completed without the patent record

The following deliverables are standard for a comprehensive analysis but cannot be generated from the current inputs:

  • Independent claim element breakdown with enforceability notes
  • Criticality ranking of claim limitations (what is likely essential vs optional)
  • Claim construction pressure points (term ambiguity, means-plus-function likelihood, prosecution history estoppel hooks)
  • Prior art list ordered by closeness with pinpoint mapping to each element
  • Family tree with related continuations and their claim differences
  • Competitive set of likely non-infringing design-arounds grounded in actual claim limitations

Key Takeaways

  • A complete and critical analysis of US Patent 5,502,034 requires the patent’s claim text, specification definitions, and prosecution history.
  • The request provides only the patent number and does not include the underlying patent record necessary for accurate claim interpretation, validity risk profiling, or prior-art mapping.

FAQs

1. Can you analyze claim scope without the claim text?

No. Claim scope analysis is inseparable from the actual claim language and defined terms in the specification.

2. Can you assess validity risk without prosecution history?

No. Validity risk depends on examiner citations, amendments, and arguments that determine what was allowed and what was surrendered.

3. Can you map prior art without claim element breakdown?

No. Prior-art mapping requires a limitation-by-limitation chart driven by the exact independent and dependent claim elements.

4. Can you identify key competitors without a CPC/field-based search?

No. A landscape assessment needs classification-driven searching and family/assignee/assignment data.

5. Does the patent number alone support a defensible landscape analysis?

No. A patent number alone does not provide the claim content, bibliographic metadata, or family/prosecution details required for a complete analysis.


References

[1] United States Patent 5,502,034. (Bibliographic and full-text claim/specification/prosecution record not provided in the request.)

More… ↓

⤷  Start Trial

Details for Patent 5,502,034

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Baxter Healthcare Corporation RECOTHROM thrombin topical (recombinant) For Solution 125248 January 17, 2008 ⤷  Start Trial 2015-06-05
Baxter Healthcare Corporation RECOTHROM thrombin topical (recombinant) For Solution 125248 May 23, 2008 ⤷  Start Trial 2015-06-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.